Using its technical platforms, Omnio AB is refining innovations and scientific breakthroughs to commercially durable product candidates in diagnostics and pharmaceuticals.
Uminova Science Park
907 19 Umeå
Omnio AB is a pioneer company in combating inflammatory diseases, especially diabetic wounds, with novel drug candidates based on a series of conceptual breakthroughs in inflammation research.
The research founding the basis of Omnio AB opens up a completely new therapeutic strategy for wound healing and anti-infection management. To reach a rapid clinical proof of concept, diabetic wound indications has been selected as the first to enter in the clinical development. Omnio’s main project is currently at the gate to enter clinical development during 2015.